Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Clinical trial NCT03267940 · TERMINATED

Trial details

NCT number: NCT03267940
Sponsor: Halozyme Therapeutics
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Cholangiocarcinoma Non-resectable Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Gallbladder Adenocarcinoma

Start date: 2017-10-02
Primary completion: 2019-11-11
Enrollment: 85

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.